Using Antibiotics Wisely - An Antimicrobial Stewardship Program

Antimicrobial Resistance Clinical Trial

Official title: Using Antibiotics Wisely - Development of National Neonatal Intensive Care Unit-specific ASP

Status Recruiting

Clinical Trial Summary

There are significant variations in antimicrobial consumption across Canadian Neonatal Intensive Care Units (NICUs). Inappropriate and overuse of antibiotics can result in antimicrobial resistance and adverse outcomes among vulnerable neonatal populations. There are limited data on broad-spectrum antimicrobial use, multi-drug resistant organisms (MDRO) prevalence, and effective NICU-specific antimicrobial stewardship strategies. The aim of this study is to develop and implement NICU-specific antimicrobial stewardship strategies at both national and individual unit levels to promote optimal antimicrobial use and decrease the incidence of MDROs.

Clinical Trial Description

Purpose: The investigators aim to develop and implement NICU-specific Antimicrobial Stewardship Program (ASP) strategies at both national and individual unit levels to promote optimal antimicrobial use and decrease the incidence of multi-drug resistant organisms (MDRO) in Canada.

Hypothesis: The investigators expect to find:

• Significant national variation in broad-spectrum antimicrobial use, which will not be correlated with rates of sepsis. High antimicrobial consumption rates may be associated with limited existing ASP resources and increased neonatal morbidity related to inflammatory cascades.

• Significant national variation in the prevalence of MDROs across NICUs.

• Differences in empirical antimicrobial regimens may be associated with MDRO prevalence, and the variation in antimicrobial use may explain some variation in neonatal morbidity.

Study Population and Sample Size: The study population will include very-low-birth-weight (VLBW) infants (i.e., the group of infants neonates with the highest risk of infections within NICUs) admitted to participating tertiary NICUs in Canada. ;

Related Conditions & MeSH terms

• Antimicrobial Resistance
• Late-Onset Sepsis, Neonatal
• Multi-Drug Resistant Organisms
• Neonatal Sepsis

• NCT number: NCT04388293
• Study type: Observational [Patient Registry]
• Source: University of British Columbia
• Contact: Joseph Ting, Associate Prof
• Phone: +1(780)248-5408
• Email: joseph.ting@ualberta.ca
• Status: Recruiting
• Start date: January 1, 2020
• Completion date: September 30, 2025